143 related articles for article (PubMed ID: 20189981)
1. Efficacy of sunitinib in advanced medullary thyroid carcinoma: intermediate results of phase II THYSU.
Ravaud A; de la Fouchardière C; Asselineau J; Delord JP; Do Cao C; Niccoli P; Rodien P; Klein M; Catargi B
Oncologist; 2010; 15(2):212-3; author reply 214. PubMed ID: 20189981
[TBL] [Abstract][Full Text] [Related]
2. Response to sunitinib in medullary thyroid cancer.
Kelleher FC; McDermott R
Ann Intern Med; 2008 Apr; 148(7):567. PubMed ID: 18378960
[No Abstract] [Full Text] [Related]
3. Three cases of sporadic medullary thyroid carcinoma in progression treated with sunitinib.
Currás Freixes M; Díaz Pérez JÁ; Casado Herráez A; Ochagavía Cámara S
Endocrinol Nutr; 2014 Jan; 61(1):62-3. PubMed ID: 24125629
[No Abstract] [Full Text] [Related]
4. Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer.
Fagin JA; Tuttle RM; Pfister DG
J Clin Endocrinol Metab; 2010 Jun; 95(6):2621-4. PubMed ID: 20525911
[No Abstract] [Full Text] [Related]
5. A case of advanced medullary thyroid carcinoma successfully treated with sunitinib.
Bugalho MJ; Domingues R; Borges A
Oncologist; 2009 Nov; 14(11):1083-7. PubMed ID: 19887470
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant treatment of unresectable medullary thyroid cancer with sunitinib.
Cleary JM; Sadow PM; Randolph GW; Palmer EL; Lynch TP; Nikiforov YE; Wirth LJ
J Clin Oncol; 2010 Aug; 28(23):e390-2. PubMed ID: 20567012
[No Abstract] [Full Text] [Related]
7. Synergistic cooperation between sunitinib and cisplatin promotes apoptotic cell death in human medullary thyroid cancer.
Lopergolo A; Nicolini V; Favini E; Dal Bo L; Tortoreto M; Cominetti D; Folini M; Perego P; Castiglioni V; Scanziani E; Borrello MG; Zaffaroni N; Cassinelli G; Lanzi C
J Clin Endocrinol Metab; 2014 Feb; 99(2):498-509. PubMed ID: 24276455
[TBL] [Abstract][Full Text] [Related]
8. A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study.
Ravaud A; de la Fouchardière C; Caron P; Doussau A; Do Cao C; Asselineau J; Rodien P; Pouessel D; Nicolli-Sire P; Klein M; Bournaud-Salinas C; Wemeau JL; Gimbert A; Picat MQ; Pedenon D; Digue L; Daste A; Catargi B; Delord JP
Eur J Cancer; 2017 May; 76():110-117. PubMed ID: 28301826
[TBL] [Abstract][Full Text] [Related]
9. The emerging role of sunitinib in the treatment of advanced epithelial thyroid cancer: our experience and review of literature.
Pasqualetti G; Ricci S; Dardano A; Ferdeghini M; Del Tacca M; Monzani F
Mini Rev Med Chem; 2011 Aug; 11(9):746-52. PubMed ID: 21707530
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib for the treatment of thyroid cancer.
Gómez-Sáez JM
Expert Opin Investig Drugs; 2016 Nov; 25(11):1345-1352. PubMed ID: 27677828
[TBL] [Abstract][Full Text] [Related]
11. Phase 2 clinical trial of sunitinib as adjunctive treatment in patients with advanced differentiated thyroid cancer.
Bikas A; Kundra P; Desale S; Mete M; O'Keefe K; Clark BG; Wray L; Gandhi R; Barett C; Jelinek JS; Wexler JA; Wartofsky L; Burman KD
Eur J Endocrinol; 2016 Mar; 174(3):373-80. PubMed ID: 26671977
[TBL] [Abstract][Full Text] [Related]
12. Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer.
Lin CI; Whang EE; Lorch JH; Ruan DT
Surgery; 2012 Dec; 152(6):1142-9. PubMed ID: 23158184
[TBL] [Abstract][Full Text] [Related]
13. Hematologic toxicity in patients treated with sunitinib for advanced thyroid cancer.
Gkountouvas A; Kostoglou-Athanassiou I; Veniou E; Repousis P; Ziras N; Kaldrimidis P
Thyroid; 2010 Jun; 20(6):597-600. PubMed ID: 20553195
[TBL] [Abstract][Full Text] [Related]
14. Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma.
Dawson SJ; Conus NM; Toner GC; Raleigh JM; Hicks RJ; McArthur G; Rischin D
Anticancer Drugs; 2008 Jun; 19(5):547-52. PubMed ID: 18418222
[TBL] [Abstract][Full Text] [Related]
15. Off-label use of sunitinib in patients with advanced, epithelial thyroid cancer: a retrospective analysis.
Pasqualetti G; Ricci S; Boni G; Tognini S; Polini A; Mariani G; Ferdeghini M; Monzani F
Recent Pat Endocr Metab Immune Drug Discov; 2012 May; 6(2):171-6. PubMed ID: 22533521
[TBL] [Abstract][Full Text] [Related]
16. Activity and Safety of Sunitinib in Patients with Advanced Radioiodine Refractory Thyroid Carcinoma: A Retrospective Analysis of 57 Patients.
Atallah V; Hocquelet A; Do Cao C; Zerdoud S; De La Fouchardiere C; Bardet S; Italiano A; Dierick-Galet A; Leduc N; Bonichon F; Leboulleux S; Godbert Y
Thyroid; 2016 Aug; 26(8):1085-92. PubMed ID: 27370404
[TBL] [Abstract][Full Text] [Related]
17. Hypothyroidism and Thyroid Autoimmunity as a Prognostic Biomarker of Better Response in Metastatic Cancer Long-Term Survivors Treated with Sunitinib.
Pani F; Atzori F; Baghino G; Boi F; Ionta MT; Tanca L; Scartozzi M; Mariotti S
Thyroid; 2016 Sep; 26(9):1336-7. PubMed ID: 27267354
[No Abstract] [Full Text] [Related]
18. Partial remission of metastatic papillary thyroid carcinoma with sunitinib. Report of a case and review of the literature.
Kaldrymides P; Kostoglou-Athanassiou I; Gkountouvas A; Veniou E; Ziras N
Endocrine; 2010 Feb; 37(1):6-10. PubMed ID: 20963554
[TBL] [Abstract][Full Text] [Related]
19. Anlotinib for the Treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid Cancer.
Sun Y; Du F; Gao M; Ji Q; Li Z; Zhang Y; Guo Z; Wang J; Chen X; Wang J; Chi Y; Tang P
Thyroid; 2018 Nov; 28(11):1455-1461. PubMed ID: 30142994
[TBL] [Abstract][Full Text] [Related]
20. Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells.
Wang W; Zhou J; Zhao L; Chen S
Biomed Pharmacother; 2017 Apr; 88():985-990. PubMed ID: 28178630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]